High-Quality Research Facility for Engitix in White City, London
The Bulb team is delighted to be creating a new high-quality facility for Engitix, a UCL spin-out, pioneering human extracellular matrix (ECM)-based discovery platform.
Engitix is pioneering a portfolio of programmes in fibrosis and solid tumours using their proprietary human extracellular matrix (ECM)-based discovery platform. The use of physiologically more relevant human in vitro models is transforming the team’s ability to identify new therapeutic drug targets, determine mechanisms of action, and increase the success rate of the discovery process.
Engitix recently signed a significant Collaboration and Licensing Agreement with Takeda, a global pharmaceutical company, to develop Anti-Fibrotic Therapies in Advanced Liver Diseases (more details).
The new facility will be based at the prestigious White City Place, London. Bulb Laboratories have been appointed to design and fit-out the space that includes bespoke laboratories and modern, open-plan offices.
Our Contracts Manager, Neil Anderson, is on the site, and the project is expected to finish at the end of November.
Watch out for the finished project pictures soon.